Lupin receives approval for Sildenafil tablets

Lupin announced that it has received approval for its Sildenafil Tablets USP, 25mg, 50mg and 100mg from the United States Food and Drug Administration (USFDA) to market a generic version of Pfizer’s viagra tablets.

Sildenafil tablets are phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED). Sildenafil USP, 25mg, 50mg, 100mg had annual sales of US$611 million in the US market.

Lupin on Friday had launched generic Levothyroxine Sodium tablets USP after receiving approval from the USFDA. This product is a generic version of AbbVie Inc’s Synthroid tablets. The tablets are supplemental therapy for hypothyroidism.

In Q3FY19, the company reported revenues of Rs. 4,505 crore, up 13.3 per cent as against Rs. 3,976 crore in the corresponding quarter last year. The company's EBITDA increased to Rs. 752.5 crore, up 9.3 per cent from Rs. 688 crore. The net loss for the company stood at Rs. 153.59 crore as against a profit of Rs. 221.64 crore in the corresponding period last year.

On Monday, Lupin was trading at Rs.733.85 per share, down 1.3 per cent on the BSE.